Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Impact Biomedicines (US)

Impact Biomedicines is pioneering the development of life changing treatments for patients with complex cancers. The Company's pipeline is centered around fedratinib, a highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was financed by Medicxi and Oberland Capital. *

 

Period Start 2018-01-07 existent
  Group Bristol Myers Squibb (BMS) (Group)
Products Industry JAK2 inhibitor
  Industry 2 fedratinib
     
Region Region San Diego, CA
  Country United States (USA)
  Street 12526 High Bluff Drive
  City 92130 San Diego, CA
  Tel +1-858-221-0950
    Address record changed: 2024-01-05
     
Basic data Employees n. a.
     
    * Document for »About Section«: Celgene Corporation. (1/7/18). "Press Release: Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies". Summit, NJ & San Diego, CA.
     
   
Record changed: 2023-07-10

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Bristol Myers Squibb (BMS) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px




» top